Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

DKK2 blockage-mediated immunotherapy enhances anti-angiogenic therapy of Kras mutated colorectal cancer.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie - 1 Jul 2020

Hu Jiajia, Wang Zhengting, Chen Zhengxi, Li Ao, Sun Jing, Zheng Minhua, Wu Jibo, Shen Tianli, Qiao Ju, Li Lin, Li Biao, Wu Dianqing, Xiao Qian

Abstract excerpt

There are limited options for targeted therapies for colorectal cancer (CRC). Anti-EGFR therapy is limited to CRC without KRAS mutations. Even worse, most of CRC are refractory to currently immune checkpoint blockade. DKK2, which is upregulated in CRC, was recently found to suppress host immune responses, and its blockage effectively impeded tumor progression in benign genetic CRC models in our previous study....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies
Share to CD8-Positive T-Lymphocytes

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Synergism

Share to Immunotherapy

Share to Intercellular Signaling Peptides and Proteins

Share to Neovascularization, Pathologic

Share to Proto-Oncogene Proteins p21(ras)

Share to Receptors, Vascular Endothelial Growth Factor

Source

Open in PubMed Open full text

Identifiers

PMID: 32559853
DOI: 10.1016/j.biopha.2020.110229
PMCID: PMC7523634

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

DKK2 blockage-mediated immunotherapy enhances anti-angiogenic therapy of Kras mutated colorectal cancer.PMID 32559853Read ↗

SH2D2A as a VEGF pathway-related oncogene driving colorectal cancer through mTOR activationSemantic proximity Read ↗

Dickkopf 1 impairs the tumor response to PD-1 blockade by inactivating CD8+ T cells in deficient mismatch repair colorectal cancerSemantic proximity Read ↗

NFKB2 mediates colorectal cancer cell immune escape and metastasis in a STAT2/PD‐L1‐dependent mannerSemantic proximity Read ↗

KMT2C mutation as a predictor of immunotherapeutic efficacy in colorectal cancer.Semantic proximity Read ↗

Furin sustains tumor-promoting signals in KRAS- and BRAF-mutated colorectal cancer by engaging the TGF-β1-COX-2 axis in a reciprocal regulatory network.Semantic proximity Read ↗

MAPKAP Kinase-2 Drives Expression of Angiogenic Factors by Tumor-Associated Macrophages in a Model of Inflammation-Induced Colon Cancer.Semantic proximity Read ↗

ERBB2 deficiency enhances colorectal cancer progression through EGFR-dependent compensatory mechanismsSemantic proximity Read ↗

Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatmentSemantic proximity Read ↗

RGL2 Drives the Metastatic Progression of Colorectal Cancer via Preventing the Protein Degradation of β-catenin and KRASSemantic proximity Read ↗

Targeting KRAS in colorectal cancer immunotherapy: rationale, challenges and future directions.Semantic proximity Read ↗

Development of therapeutic monoclonal antibodies against DKK1 peptide-HLA-A2 complex to treat human cancersSemantic proximity Read ↗

DKC1 enhances angiogenesis by promoting HIF-1α transcription and facilitates metastasis in colorectal cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.